Gholamzadeh Baeis Mehdi, Amiri Ghasem, Miladinia Mojtaba
Young Researchers and Elites Club, Qom Branch, Islamic Azad University, Qom, Iran.
Infectious disease specialist, Qom University of Medical Sciences, Qom, Iran.
Avicenna J Phytomed. 2017 May-Jun;7(3):232-241.
This study examines the effect of the addition of IMOD, a novel multi-herbal drug to the highly active anti-retroviral therapy (HAART) regimen, on the immunological status of HIV-positive patients.
A randomized two-parallel-group (HAART group versus HAART+IMOD group), pretest-posttest design was used.Sixty patients with indications for treatment with the HAART regimen participated. One week before and 2 days after the treatments, immunological parameters including total lymphocyte count (TLC) and CD4 cell count were assessed.The intervention group received the HAART regimen plus IMOD every day for 3 months. The control group received only the HAART regimen every day for 3 months.
In the intervention group, a significant difference was observed in CD4between before and after drug therapy (CD4 was increased). However, in the control group, the difference in CD4 was not significant before and after drug therapy. The difference in TLC was not significantly different between the two groups before and after therapy. Nevertheless, TLC was higher in the intervention group.
IMOD (as a herbal drug) has been successfully added to the HAART regimen to improve the immunological status of HIV-positive patients.
本研究探讨在高效抗逆转录病毒治疗（HAART）方案中添加新型多草药药物IMOD对HIV阳性患者免疫状态的影响。
采用随机双平行组（HAART组与HAART + IMOD组）、治疗前后测试设计。60例有HAART方案治疗指征的患者参与研究。在治疗前1周和治疗后2天，评估包括总淋巴细胞计数（TLC）和CD4细胞计数在内的免疫参数。干预组每天接受HAART方案加IMOD，持续3个月。对照组每天仅接受HAART方案，持续3个月。
干预组在药物治疗前后CD4有显著差异（CD4增加）。然而，对照组在药物治疗前后CD4差异不显著。两组治疗前后TLC差异无统计学意义。尽管如此，干预组的TLC较高。
IMOD（作为一种草药药物）已成功添加到HAART方案中，以改善HIV阳性患者的免疫状态。
